Novel antimicrobial agents against multi-drug-resistant gram-negative bacteria: An overview

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 3, 2012, Pages 175-181

  Karras, George ^a,b   Giannakaki, Venetia ^a,b   Kotsis, Vasilios ^a   Miyakis, Spiros ^a,b,c,d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d WOLLONGONG HOSPITAL   (Australia)

Author keywords

Acinetobacter; Antimicrobials; Carbapenemase; Enterobacteriaceae; Multidrug resistance; Pseudomonas aeruginosa

Indexed keywords

6 (5,6 DIHYDRO 8H IMIDAZO[2,1 C][1,4]OXAZIN 2 YLMETHYLENE) 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; ANTIINFECTIVE AGENT; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; BAL 30072; CAZ 104; CEFTAROLINE; CEFTOBIPROLE; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; CXA 201; DELAFLOXACIN; ERAVACYCLINE; EXTENDED SPECTRUM BETA LACTAMASE; FSI 1686; GENTAMICIN; GSK 2251052; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MK 7655; OMADACYCLINE; PIPERACILLIN; PLAZOMICIN; POLYPEPTIDE ANTIBIOTIC AGENT; PYRROLOCYTOSINE DERIVATIVE; SOLITHROMYCIN; SULBACTAM; TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PATENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84870184767     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112803521922     Document Type: Article

References (82)

1. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis 2011; 53: 177-84.
2. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
3. Moya B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, et al. Pan-beta-lactam Resistance Development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, pbps profiles and binding affinities. Antimicrob Agents Chemother 2012; 56: 4771-8.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
5. Infectious Diseases Society of America. The 10 x '20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-3.
6. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, et al. Combating antimicrobial resistance: Policy recommendations to save lives. Clin Infect Dis 2011; 52: S397-428.
7. Peleg AY, Hooper DC. Hospital-acquired infections due to gramnegative bacteria. N Engl J Med 2010; 362: 1804-13.
8. Pitout JD, Laupland KB. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
9. Queenan AM, Bush K. Carbapenemases: The versatile betalactamases. Clin Microbiol Rev 2007; 20: 440-58, table of contents.
10. Mammeri H, Van De Loo M, Poirel L, Martinez-Martinez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49: 71-6.
11. Poulou A, Spanakis N, Pournaras S, Pitiriga V, Ranellou K, Markou F, et al. Recurrent healthcare-associated community-onset infections due to Klebsiella pneumoniae producing VIM-1 metallobeta-lactamase. J Antimicrob Chemother 2010; 65: 2538-42.
12. Livermore DM. Role of beta-lactamase and impermeability in the resistance of Pseudomonas aeruginosa. Antibiot Chemother 1989; 42: 257-63.
13. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 413-20.
14. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-36.
15. Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA. Review of ceftaroline fosamil microbiology: Integrated FOCUS studies. J Antimicrob Chemother 2011; 66: 45-51.
16. Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: A novel, broadspectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 2010; 67: 983-93.
17. Poon H, Chang MH, Fung HB. Ceftaroline fosamil: A cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Ther 2012; 34: 743-65.
18. Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: Doripenem, ceftobiprole, ceftaroline, and cefepime. Infect Dis Clin North Am 2009; 23: 983-96.
19. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011; 55: 2390-4.
20. Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011; 70: 137-41.
21. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother 2012; 56: 544-9.
22. Citri N, Pollock MR. The biochemistry and function of betalactamase (penicillinase). Adv Enzymol Relat Areas Mol Biol 1966; 28: 237-323.
23. Bebrone C, Lassaux P, Vercheval L, Sohier JS, Jehaes A, Sauvage E, et al. Current challenges in antimicrobial chemotherapy: Focus on ss-lactamase inhibition. Drugs 2010; 70: 651-79.
24. Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 2005; 56: 463-9.
25. Sianou E, Kristo I, Petridis M, Apostolidis K, Meletis G, Miyakis S, et al. A cautionary case of microbial solidarity: Concurrent isolation of VIM-1-producing Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae from an infected wound. J Antimicrob Chemother 2012; 67: 244-6.
26. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, et al. Avibactam is a covalent, reversible, non-beta-lactam betalactamase inhibitor. Proc Natl Acad Sci USA 2012; 109: 11663-8
27. Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, et al. In vitro antibacterial activity of the ceftazidimeavibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012; 56: 1606-8.
28. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types. Antimicrob Agents Chemother 2012; 56: 4779-85.
29. Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39: 86-9.
30. Ruzin A, Petersen PJ, Jones CH. Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489. J Antimicrob Chemother 2010; 65: 252-7.
31. Petersen PJ, Jones CH, Venkatesan AM, Bradford PA. Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob Agents Chemother 2009; 53: 1698-700.
32. Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA. Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. Antimicrob Agents Chemother 2009; 53: 370-84.
33. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenemresistant gram-negative bacteria. Antimicrob Agents Chemother 2012; 56: 3753-7.
34. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56: 432-6.
35. Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother 2010; 54: 2291-302.
36. Mushtaq S, Warner M, Livermore D. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 2010; 65: 266-70.
37. Mima T, Kvitko BH, Rholl DA, Page MG, Desarbre E, Schweizer HP. In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 2011; 38: 157-9.
38. Russo TA, Page MG, Beanan JM, Olson R, Hujer AM, Hujer KM, et al. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother 2011; 66: 867-73.
39. Higgins PG, Stefanik D, Page MG, Hackel M, Seifert H. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 2012; 67: 1167-9.
40. Joo H, Kim D, Kowalik E, Liu S, Li Y, Mao S, et al. FSI-1686, a novel-ethylcarbapenem; in vitro activity against carbapenemresistance gram-negative bacteria. Proceedings of the 51st ICAAC. Chicago, Il, 2011; F1-142.
41. Joo H, Kim D, Kowalik E, Liu S, Li Y, Mao S, et al. Efficacy of FSI-1686 in animal model of carbapenem-resistance gram-negative bacterial infection. Proceedings of the 51st ICAAC. Chicago, Il, 2011; F1-143.
42. Bush K. Improving known classes of antibiotics: An optimistic approach for the future. Curr Opin Pharmacol 2012; 12: 527-34.
43. Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012; 10: 459-73.
44. Remy JM, Tow-Keogh CA, Mcconnell TS, Dalton JM, Devito JA. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: Resistance selection and characterization. J Antimicrob Chemother 2012 [Epub ahead of print].
45. Bowser T, Bhatia B, Chen J, Ismail M, Mcintyre L, Mechiche R, et al. PTK 0796 and other novel tetracycline derivatives exhibiting potent in vitro and in vivo activities against antibiotic resistant Gram-positive bacteria. Proceedings of the 43rd ICAAC. Chicago, Il, 2003, F-755.
46. Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit R. A randomized, evaluator blind, phase 2 study comparing safety and efficacy of omadacycline to linezolid for the treatment of complicated skin and skin-structure infections. Antimicrob Agents Chemother 2012 [Epub ahead of print].
47. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 2011; 1241: 122-52.
48. Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, et al. Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012; 56: 2559-64.
49. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012; 56: 2739-42.
50. Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother 2012; 56: 5076-81.
51. Chevalier J, Mahamoud A, Baitiche M, Adam E, Viveiros M, Smarandache A, et al. Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int J Antimicrob Agents 2010; 36: 164-8.
52. Mahamoud A, Chevalier J, Baitiche M, Adam E, Pages JM. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates. Microbiology 2011; 157: 566-71.
53. Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol 2011; 11: 433-8.
54. Butler MM, Nguyen ST, Williams JD, Ding X, Tashjian TF, Podnecky NL, et al. Bis-amidine antibacterials display structurespecific resistance to efflux in gram-negative bacteria. Proceedings of the 51st ICAAC. Chicago, Il, 2011, F1-157
55. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
56. Huang Y, Huang J, Chen Y. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell 2010; 1: 143-52.
57. Yu HY, Huang KC, Yip BS, Tu CH, Chen HL, Cheng HT, et al. Rational design of tryptophan-rich antimicrobial peptides with enhanced antimicrobial activities and specificities. Chembiochem 2010; 11: 2273-82.
58. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol 2011; 29: 464-72.
59. Xiong YQ, Yeaman MR, Bayer AS. Thrombin-induced platelet microbicidal proteins (tPMPs) inhibit macromolecular synthesis in Staphylococcus aureus. 100th General Meeting of the Americal Society for Microbiology Los Angeles, CA, 2000, A111.
60. Kawasaki K, Ernst RK, Miller SI. Inhibition of Salmonella enterica serovar Typhimurium lipopolysaccharide deacylation by aminoarabinose membrane modification. J Bacteriol 2005; 187: 2448-57.
61. Kang SJ, Kim DH, Mishig-Ochir T, Lee BJ. Antimicrobial peptides: Their physicochemical properties and therapeutic application. Arch Pharm Res 2012; 35: 409-13.
62. Rozgonyi F, Szabo D, Kocsis B, Ostorhazi E, Abbadessa G, Cassone M, et al. The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr Med Chem 2009; 16: 3996-4002.
63. Szabo D, Ostorhazi E, Binas A, Rozgonyi F, Kocsis B, Cassone M, et al. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models. Int J Antimicrob Agents 2010; 35: 357-61.
64. Tenero DM, Zane LT, Tomayko JF. Use of a Population Pharmacokinetic Model for Dose Selection in Phase IIb Studies for GSK2251052. Proceedings of the 51st ICAAC. Chicago, Il, 2011, A2-023.
65. Wu G, Wu H, Fan X, Zhao R, Li X, Wang S, et al. Selective toxicity of antimicrobial peptide S-thanatin on bacteria. Peptides 2010; 31: 1669-73.
66. Wu G, Li X, Deng X, Fan X, Wang S, Shen Z, et al. Protective effects of antimicrobial peptide S-thanatin against endotoxic shock in mice introduced by LPS. Peptides 2011; 32: 353-7.
67. Cirioni O, Wu G, Li L, Orlando F, Silvestri C, Ghiselli R, et al. Sthanatin enhances the efficacy of tigecycline in an experimental rat model of polymicrobial peritonitis. Peptides 2010; 31: 1231-6.
68. Wu G, Fan X, Li L, Wang H, Ding J, Hongbin W, et al. Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli. Int J Antimicrob Agents 2010; 35: 250-4.
69. Wu G, Deng X, Wu P, Shen Z, Xu H. Subacute toxicity of antimicrobial peptide S-thanatin in ICR mice. Peptides 2012; 36: 109-13.
70. Scheideman M, Bhattacharjee A, Chen S, Dalton J, Devito J, Devivo M, et al. Completely novel antibiotics for treating multidrug-resistant gram-negative infections: The phenoxazinocytosines. Proceedings of the 51st ICAAC. Chicago, Il, 2011, F1-1844.
71. Lamb L, Crandon JL, Nicolau DP. Pharmacodynamic assessments of RX-P873 against Klebsiella pneumoniae using the murine thigh infection model. Proceedings of the 52nd ICAAC. San Francisco, CA, 2012, F-2072a.
72. Bhattacharjee A, Chen S, Collin F, Dalton J, Devito J, Devivo M, et al. Completely novel antibiotics for treating multidrug-resistant gram-negative infections: The pyrrolocytosines. Proceedings of the 51st ICAAC. Chicago, Il, 2011, F1-1846.
73. Sinishtaj S, Bhattacharjee A, Chen S, Collin F, Dalton J, Devito J, et al. Completely novel antibiotics for treating multidrug-resistant gram-negative infections: The isocytosine ureas. Proceedings of the 51st ICAAC. Chicago, Il, 2011, F1-1845.
74. Onyuksel, H., Rubinstein, I. Phospholipid micellar and liposomal compositions and uses thereof. US20110256213A1 (2011).
75. Yousef, A.E., He, Z., Yuan, C., Zhang, L., Kisla, D. Antibiotic Antimicrobial agents and methods of their use. US20110245152A1 (2011).
76. Cheng, J., Huang, K., Cheng, H., Yu, H. Low hemolytic antimicrobial peptide, pharmaceutical composition and uses thereof. WO2011120359A1 (2011).
77. Schweizer, F., Smritilekha, B., Zhanel, G. Polyol modified aminoglycoside-lipid conjugates. WO2011124986A2 (2011)
78. Fitzpatrick, L., Hoerr, R.A., Bostwick, E.F. Biotherapeutic compositions comprising probiotic Escherichia coli and Metronidazole and uses thereof. EP2040724B1 (2011).
79. Goddard S, Muller MP. The efficacy of infection control interventions in reducing the incidence of extended-spectrum betalactamase-producing Enterobacteriaceae in the nonoutbreak setting: A systematic review. Am J Infect Control 2011; 39: 599-601.
80. ClinicalTrials. gov. Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections. Available at: http://clinicaltrials. gov/ct2/show/NCT01147640?term=cxa101+tazobactam&rank=1.ht ml. (Accessed on: September 29, 2012).
81. ClinicalTrials. gov. Study for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Available at: http://clinicaltrials.gov/ct2/show/NCT01096849?term=PLAZOMI CIN&rank=5.html. (Accessed on: September 20, 2012).
82. ClinicalTrials. gov. Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea. Available at: http://clinicaltrials.gov/ct2/show/NCT01591447? term=solithromycin&rank=1.html. (Accessed on: September 29, 2012)